| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/14/2013 | WO2013022991A2 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
| 02/14/2013 | WO2013022924A1 Pharmaceutical formulations |
| 02/14/2013 | WO2013022783A2 Progesterone containing oral dosage forms and related methods |
| 02/14/2013 | WO2013022410A2 Production method for effervescent formulations comprising dexketoprofen |
| 02/14/2013 | WO2013022201A1 Process of preparing a stabilized and solubilized formulation of sirolimus derivatives |
| 02/14/2013 | WO2013022090A1 Highly functional cellulose composite |
| 02/14/2013 | WO2013022059A1 Pharmaceutical composition containing diamine derivative |
| 02/14/2013 | WO2013021935A1 Compound for treating cartilage disorders |
| 02/14/2013 | WO2013021660A1 Coated preparation containing azosemide as active ingredient |
| 02/14/2013 | WO2013021396A1 Ointment for treatment of wound |
| 02/14/2013 | WO2013021302A1 Anti-oxidant herbal composition |
| 02/14/2013 | WO2013021295A1 Plant extracts composition for the treatment of liver dysfunction |
| 02/14/2013 | WO2013021249A1 Degradation-resistant cross-linked, low-molecular-weight hyaluronate |
| 02/14/2013 | WO2013021199A2 Pharmaceutical compositions |
| 02/14/2013 | WO2013021143A1 Injectable solution of at least one type of basal insulin |
| 02/14/2013 | WO2013021139A1 Solid pharmaceutical composition for orally delivering agomelatine |
| 02/14/2013 | WO2013020917A1 Ophthalmologic composition comprising an aqueous solution of at least one viscoelastic polysaccharide |
| 02/14/2013 | WO2013020899A1 Multiple emulsion |
| 02/14/2013 | WO2013020527A1 Utilization of alaptide as transdermal penetration modifier in pharmaceutical compositions for human and veterinary applications containing anti-inflammatory drugs and/or antimicrobial chemotherapeutics |
| 02/14/2013 | WO2013020302A1 Diclofenac sodium sustained release tablet and preparation process therefor |
| 02/14/2013 | WO2013020243A1 Pharmaceutical composition containing insoluble medicine |
| 02/14/2013 | WO2013020242A1 Spray formulation of mesenchymal stem cells for the treatment of chronic wounds |
| 02/14/2013 | WO2013020204A1 Polymeric nanoparticles for photosensitizers |
| 02/14/2013 | WO2013020182A1 Antioxidant topical compositions |
| 02/14/2013 | WO2012173003A3 Medical tissue-marker and manufacturing method for same |
| 02/14/2013 | WO2012150607A3 Oral liquid composition comprising divalproex sodium and process for preparing thereof |
| 02/14/2013 | WO2004112836A8 Ophthalmic compositions containing a synergistic combination of two polymers |
| 02/14/2013 | US20130041311 Methods, devices, and systems for on-demand ultrasound-triggered drug delivery |
| 02/14/2013 | US20130041307 Application of beta-functionalized dihydroxy-chlorins for pdt |
| 02/14/2013 | US20130041006 Pharmaceutical composition for intracellar acidification with cis-urocanic acid |
| 02/14/2013 | US20130040817 Capsule comprising active ingredient |
| 02/14/2013 | US20130040141 Method for producing crystalline active ingredient particles |
| 02/14/2013 | US20130039990 Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering |
| 02/14/2013 | US20130039989 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide |
| 02/14/2013 | US20130039988 Active pellet excluding chemical additives |
| 02/14/2013 | US20130039987 Method for increasing the solubility of a transcriptase inhibitor composition |
| 02/14/2013 | US20130039986 Silk-Based Ionomeric Compositions |
| 02/14/2013 | US20130039985 Method for aligning cells and applying homogenous strain throughout deformable engineered tissue constructs |
| 02/14/2013 | US20130039984 Manufacture process for the preparation of an iron containing phosphate adsorbent |
| 02/14/2013 | US20130039983 Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects |
| 02/14/2013 | US20130039982 Low-dose tablets and preparation process |
| 02/14/2013 | US20130039981 Quick Dissolving, Long Acting Zinc Therapeutic Formulations |
| 02/14/2013 | US20130039980 Time Release Capsule for Beverage |
| 02/14/2013 | US20130039979 Medication on the basis of 3,3'-diindolylmethane (dim) with high-bioavailability and its use in treatment of human hyperplastic and inflammatory diseases |
| 02/14/2013 | US20130039978 Medicinal compositions and method for treatment of urinary tract infections |
| 02/14/2013 | US20130039977 Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof |
| 02/14/2013 | US20130039976 Sodium channel blocker for treatment of loss of superficial sensitivity |
| 02/14/2013 | US20130039975 Liposomes Containing Prostaglandin E1 (PGE1), Formulations Containing Them and Their Use |
| 02/14/2013 | US20130039974 Anti-muc1 antibodies for cancer diagnostics |
| 02/14/2013 | US20130039973 Viral Immunogenic Compositions |
| 02/14/2013 | US20130039972 Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| 02/14/2013 | US20130039971 Compositions and methods for inhibition of vegf |
| 02/14/2013 | US20130039970 Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
| 02/14/2013 | US20130039969 Method And Composition For Treating Rhinitis |
| 02/14/2013 | US20130039968 Materials and processes for producing antitoxic fabrics |
| 02/14/2013 | US20130039967 Oral dosage forms |
| 02/14/2013 | US20130039964 Metal entrapped bioactive composites |
| 02/14/2013 | US20130039960 Compositions for reduction of side effects |
| 02/14/2013 | US20130039959 Method of inhibiting hiv and barrier-forming composition therefor |
| 02/14/2013 | US20130039958 Method of vaccination |
| 02/14/2013 | US20130039957 Controlled release pharmaceutical compositions of brivaracetam |
| 02/14/2013 | US20130039956 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 02/14/2013 | US20130039955 Orally Ingested Metabolic Enhancer in Oral Thin Film Container |
| 02/14/2013 | US20130039954 Control of antibody responses to synthetic nanocarriers |
| 02/14/2013 | US20130039953 Method for treating a surface with a coating comprising a therapeutic agent and device with treated surface |
| 02/14/2013 | US20130039952 Calcipotriol monohydrate nanocrystals |
| 02/14/2013 | US20130039951 Process Of Preparing A Stabilized And Solubilized Formulation Of Sirolimus Derivatives |
| 02/14/2013 | US20130039950 Neti-pot packet mixture |
| 02/14/2013 | US20130039935 Induction of tumor immunity by variants of folate binding protein |
| 02/14/2013 | US20130039901 Treatment of Pompe's Disease |
| 02/14/2013 | US20130039879 Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers |
| 02/14/2013 | US20130039864 Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof |
| 02/14/2013 | US20130039851 Stabilizing Alkylglycoside Compositions and Methods Thereof |
| 02/14/2013 | US20130039848 Fluorescent silica-based nanoparticles |
| 02/14/2013 | US20130039847 Liposomes for pulmonary administration |
| 02/14/2013 | DE102011115173A1 Granule, useful as hot or cold drink, comprises caffeine and sucralose and Stevia/steviol glycoside and/or neohesperidin dihydrochalcone in an enclosed shell of a fat |
| 02/14/2013 | DE102011088909A1 Verfahren zur Herstellung und Kontrolle von oralen Wirkstoff-Filmen Process for the manufacture and control of oral drug movies |
| 02/14/2013 | CA2847298A1 Multiple emulsion |
| 02/14/2013 | CA2844808A1 Antioxidant topical compositions |
| 02/14/2013 | CA2844604A1 Pharmaceutical composition containing diamine derivative |
| 02/14/2013 | CA2844283A1 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
| 02/14/2013 | CA2844025A1 Pharmaceutical compositions |
| 02/14/2013 | CA2843586A1 Injectable solution of at least one type of basal insulin |
| 02/13/2013 | EP2556833A1 Pharmaceutical composition for the treatment of alzheimer's disease, method for producing same and use thereof |
| 02/13/2013 | EP2556832A1 Uridine and uridine analogues for use in the treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
| 02/13/2013 | EP2556826A1 Modified-release multiparticulate formulation of diltiazem HCL |
| 02/13/2013 | EP2556825A1 Multicomponent pharmaceutical dosage form |
| 02/13/2013 | EP2556824A1 Solid pharmaceutical composition for buccal administration of agomelatine |
| 02/13/2013 | EP2556145A1 Angiogenesis using placental stem cells |
| 02/13/2013 | EP2556085A2 Protease-activatable pore-forming polypeptides |
| 02/13/2013 | EP2556083A2 Non-hormonal steroid modulators of nf- kappa b for treatment of disease |
| 02/13/2013 | EP2555863A2 Method and device for forming vesicles, in particular using block copolymers |
| 02/13/2013 | EP2555843A1 Method for producing crystalline active ingredient particles |
| 02/13/2013 | EP2555809A1 Chitosan beads and filler comprising such beads |
| 02/13/2013 | EP2555808A1 Fillers comprising gellan or pectin beads |
| 02/13/2013 | EP2555762A2 System and method for the release of nitric oxide using nanoscale media |
| 02/13/2013 | EP2555761A1 Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids |
| 02/13/2013 | EP2555760A1 Methods and compositions for treating wounds utilizing chitosan compounds |
| 02/13/2013 | EP2555759A1 Low energy, cold process formulation aid |
| 02/13/2013 | EP2555758A1 Punctal plugs for controlled release of therapeutic agents |